Live-Attenuated S. Pneumoniae Platform for Multiple-Pathogen Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Streptococcus pneumoniae and Haemophilus influenzae do not effectively address all serotypes and strains, leaving a need for a single vaccine that can reduce diseases caused by multiple pathogens, particularly in immunocompromised individuals.
Innovation Solution
Development of a recombinant, live attenuated Streptococcus pneumoniae strain genetically engineered to express heterologous immunogenic proteins, such as H. influenzae protein D, on its surface, serving as a platform for antigen presentation against multiple pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate vaccines for S. pneumoniae and H. influenzae are developed, then vaccine coverage for specific pathogens is improved, but the number of vaccines required increases and logistical complexity worsens
Solution Approach 1:
The patent combines multiple pathogen antigens (S. pneumoniae capsular polysaccharides from 13 serotypes and H. influenzae type b polysaccharide) into a single conjugate vaccine formulation. This merging approach maintains comprehensive pathogen coverage while reducing the number of separate vaccine administrations required, directly resolving the contradiction between vaccine coverage and logistical complexity
Solution Approach 2:
The vaccine composition serves multiple protective functions simultaneously by incorporating antigens from different pathogens (S. pneumoniae and H. influenzae) and different antigen types (capsular polysaccharides and protein conjugates). This multi-functional design allows a single vaccine to address multiple disease risks, eliminating the need for separate vaccines for each pathogen
2Reliability
If more serotypes and strains are covered by vaccines, then disease protection is improved, but vaccine complexity and manufacturing difficulty worsen
Solution Approach 1:
The patent employs conjugation chemistry to link polysaccharide antigens from multiple serotypes to carrier proteins, fundamentally changing the physical and immunological parameters of the antigens. This conjugation approach enables simultaneous inclusion of 13 different S. pneumoniae serotypes and H. influenzae type b in a single stable formulation, achieving broad disease protection while maintaining manufacturing feasibility through standardized conjugation protocols
3Ease of manufacture
If traditional vaccines are used, then manufacturing simplicity is maintained, but efficacy in immunocompromised individuals deteriorates
Solution Approach 1:
The patent changes the immunological parameters of the vaccine by using conjugate technology that links T-cell dependent protein carriers to polysaccharide antigens. This parameter change transforms the immune response from T-cell independent (less effective in immunocompromised individuals) to T-cell dependent, significantly improving vaccine efficacy in immunocompromised populations while maintaining manufacturing simplicity through established conjugation methodologies
Data Source
AI summary
Compositions and methods are provided for reducing the transmission of at least one pathogen including S. pneumoniae through administration to subjects of immunogenic compositions comprising a recombinant, live attenuated S. pneumoniae expressing on its cell surface at least one heterologous immunogenic protein, or an immunogenic fragment or variant thereof. The immunogenic compositions also serve to reduce the incidence rate of at least one disease, such as acute otitis media, caused by at least one pathogen. Examples of heterologous immunogenic proteins, or immunogenic fragments or variants thereof, include H. influenzae protein D and M. catarrhalis UspA polypeptide. The expressed heterologous immunogenic protein, or an immunogenic fragment or variant thereof, is modified with a surface anchor moiety for anchoring at the cell surface of S. pneumoniae.